AIMS/HYPOTHESIS: Cytokines may promote or inhibit disease progression in type 1 diabetes. We investigated whether systemic proinflammatory, anti-inflammatory and regulatory cytokines associated differently with fasting and meal-stimulated beta cell function in patients with longer term type 1 diabetes. METHODS: The beta cell function of 118 patients with type 1 diabetes of duration of 0.75-4.97 years was tested using a standardised liquid mixed meal test (MMT). Serum samples obtained at -5 to 120 min were analysed by multiplex bead-based technology for proinflammatory (IL-6, TNF-α), anti-inflammatory (IL-1 receptor antagonist [IL-1RA]) and regulatory (IL-10, TGF-β1-3) cytokines, and by standard procedures for C-peptide. Differences in beta cell function between patient groups were assessed using stepwise multiple regression analysis adjusting for sex, age, duration of diabetes, BMI, HbA1c and fasting blood glucose. RESULTS: High fasting systemic concentrations of the proinflammatory cytokines IL-6 and TNF-α were associated with increased fasting and stimulated C-peptide concentrations even after adjustment for confounders (p < 0.03). Interestingly, increased concentrations of anti-inflammatory/regulatory IL-1RA, IL-10, TGF-β1 and TGF-β2 were associated with lower fasting and stimulated C-peptide levels (p < 0.04), losing significance on adjustment for anthropometric variables. During the MMT, circulating concentrations of IL-6 and TNF-α increased (p < 0.001) while those of IL-10 and TGF-β1 decreased (p < 0.02) and IL-1RA and TGF-β2 remained unchanged. CONCLUSIONS/ INTERPRETATION: The association between better preserved beta cell function in longer term type 1 diabetes and increased systemic proinflammatory cytokines and decreased anti-inflammatory and regulatory cytokines is suggestive of ongoing inflammatory disease activity that might be perpetuated by the remaining beta cells. These findings should be considered when designing immune intervention studies aimed at patients with longer term type 1 diabetes and residual beta cell function.
AIMS/HYPOTHESIS: Cytokines may promote or inhibit disease progression in type 1 diabetes. We investigated whether systemic proinflammatory, anti-inflammatory and regulatory cytokines associated differently with fasting and meal-stimulated beta cell function in patients with longer term type 1 diabetes. METHODS: The beta cell function of 118 patients with type 1 diabetes of duration of 0.75-4.97 years was tested using a standardised liquid mixed meal test (MMT). Serum samples obtained at -5 to 120 min were analysed by multiplex bead-based technology for proinflammatory (IL-6, TNF-α), anti-inflammatory (IL-1 receptor antagonist [IL-1RA]) and regulatory (IL-10, TGF-β1-3) cytokines, and by standard procedures for C-peptide. Differences in beta cell function between patient groups were assessed using stepwise multiple regression analysis adjusting for sex, age, duration of diabetes, BMI, HbA1c and fasting blood glucose. RESULTS: High fasting systemic concentrations of the proinflammatory cytokines IL-6 and TNF-α were associated with increased fasting and stimulated C-peptide concentrations even after adjustment for confounders (p < 0.03). Interestingly, increased concentrations of anti-inflammatory/regulatory IL-1RA, IL-10, TGF-β1 and TGF-β2 were associated with lower fasting and stimulated C-peptide levels (p < 0.04), losing significance on adjustment for anthropometric variables. During the MMT, circulating concentrations of IL-6 and TNF-α increased (p < 0.001) while those of IL-10 and TGF-β1 decreased (p < 0.02) and IL-1RA and TGF-β2 remained unchanged. CONCLUSIONS/ INTERPRETATION: The association between better preserved beta cell function in longer term type 1 diabetes and increased systemic proinflammatory cytokines and decreased anti-inflammatory and regulatory cytokines is suggestive of ongoing inflammatory disease activity that might be perpetuated by the remaining beta cells. These findings should be considered when designing immune intervention studies aimed at patients with longer term type 1 diabetes and residual beta cell function.
Authors: Marc Y Donath; Joachim Størling; Lukas A Berchtold; Nils Billestrup; Thomas Mandrup-Poulsen Journal: Endocr Rev Date: 2007-11-29 Impact factor: 19.871
Authors: Helga Ellingsgaard; Irina Hauselmann; Beat Schuler; Abdella M Habib; Laurie L Baggio; Daniel T Meier; Elisabeth Eppler; Karim Bouzakri; Stephan Wueest; Yannick D Muller; Ann Maria Kruse Hansen; Manfred Reinecke; Daniel Konrad; Max Gassmann; Frank Reimann; Philippe A Halban; Jesper Gromada; Daniel J Drucker; Fiona M Gribble; Jan A Ehses; Marc Y Donath Journal: Nat Med Date: 2011-10-30 Impact factor: 53.440
Authors: Francesco Nappo; Katherine Esposito; Michele Cioffi; Giovanni Giugliano; Anna Maria Molinari; Giuseppe Paolisso; Raffaele Marfella; Dario Giugliano Journal: J Am Coll Cardiol Date: 2002-04-03 Impact factor: 24.094
Authors: Christian Pfleger; Henrik B Mortensen; Lars Hansen; Christian Herder; Bart O Roep; Hillary Hoey; Henk-Jan Aanstoot; Mirjana Kocova; Nanette C Schloot Journal: Diabetes Date: 2008-02-25 Impact factor: 9.461
Authors: Hubert Kolb; Kathrin Lückemeyer; Tim Heise; Christian Herder; Nanette C Schloot; Wolfgang Koenig; Lutz Heinemann; Stephan Martin Journal: PLoS One Date: 2013-08-26 Impact factor: 3.240
Authors: Maritza J Romero; Lin Yao; Supriya Sridhar; Anil Bhatta; Huijuan Dou; Ganesan Ramesh; Michael W Brands; David M Pollock; Ruth B Caldwell; Stephen D Cederbaum; C Alvin Head; Zsolt Bagi; Rudolf Lucas; Robert W Caldwell Journal: Front Immunol Date: 2013-12-24 Impact factor: 7.561
Authors: Jin Ook Chung; Seon-Young Park; Dong Hyeok Cho; Dong Jin Chung; Min Young Chung Journal: Medicine (Baltimore) Date: 2018-08 Impact factor: 1.889
Authors: Kate Downes; M Loredana Marcovecchio; Pamela Clarke; Jason D Cooper; Ricardo C Ferreira; Joanna M M Howson; Jennifer Jolley; Sarah Nutland; Helen E Stevens; Neil M Walker; Chris Wallace; David B Dunger; John A Todd Journal: Diabetologia Date: 2013-11-22 Impact factor: 10.122